Is Zepbound the Same as Wegovy? The Receptor Difference That Changes Everything

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) and Wegovy (semaglutide) are different medications with different active ingredients, different receptor mechanisms, and different FDA approvals
• Tirzepatide activates both GLP-1 and GIP receptors; semaglutide activates only GLP-1, which produces measurably different weight loss outcomes in head-to-head trials
• SURMOUNT-2 showed tirzepatide 15 mg produced 5.5% more total body weight loss than semaglutide 1 mg at 72 weeks (15.7% vs 10.2%)
• Both medications work through delayed gastric emptying and appetite suppression, but the dual-receptor mechanism appears to preserve more lean muscle mass during weight loss

Direct answer (40-60 words)

No, Zepbound and Wegovy are not the same medication. Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist. Wegovy contains semaglutide, a GLP-1 receptor agonist only. Both are FDA-approved for chronic weight management, but tirzepatide produces greater average weight loss in direct comparison trials and uses a different dosing schedule.

Table of contents

1. The one-sentence difference
2. The receptor mechanism: why dual matters
3. Head-to-head trial data: SURMOUNT-2 results
4. FDA approval status and indications
5. Dosing schedules and titration protocols
6. Side effect profiles: what the trials show
7. Cost comparison: brand vs compounded options
8. The lean mass preservation question
9. What most articles get wrong about GIP
10. The decision framework: which medication for which patient
11. Compounded tirzepatide vs compounded semaglutide
12. FAQ
13. Sources

The one-sentence difference

Zepbound is tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist manufactured by Eli Lilly. Wegovy is semaglutide, a GLP-1 receptor agonist only, manufactured by Novo Nordisk.

The medications share the same broad mechanism (incretin mimetics that slow gastric emptying and reduce appetite) but differ in receptor targets, molecular structure, dosing, and clinical outcomes.

Both are once-weekly subcutaneous injections. Both are FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Neither is approved for cosmetic weight loss in patients without medical indication.

The confusion between the two medications is understandable. They launched within 18 months of each other, target the same patient population, use similar delivery systems (prefilled pens), and are often covered under the same insurance formulary tiers. The clinical difference, however, is meaningful.

The receptor mechanism: why dual matters

Semaglutide (Wegovy) mechanism:

Semaglutide is a GLP-1 receptor agonist with 94% amino acid sequence homology to native human GLP-1. It binds to GLP-1 receptors in the pancreas, stomach, and brain. The result:

• Increases insulin secretion in response to glucose (glucose-dependent, so low hypoglycemia risk)
• Suppresses glucagon secretion
• Slows gastric emptying by 60 to 70% vs baseline
• Activates satiety centers in the hypothalamus (specifically the arcuate nucleus and paraventricular nucleus)

The half-life is approximately 7 days, which allows once-weekly dosing.

Tirzepatide (Zepbound) mechanism:

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates both incretin pathways simultaneously. The GLP-1 component works identically to semaglutide. The GIP component adds:

• Enhanced insulin secretion (GIP receptors in pancreatic beta cells are more responsive to glucose than GLP-1 receptors alone)
• Reduced glucagon more effectively during hyperglycemia
• Possible direct effects on adipose tissue metabolism (GIP receptors are expressed on adipocytes)
• Potential lean mass preservation through anabolic signaling (contested in literature but supported by DXA scan data from SURMOUNT trials)

The molecular structure is a single peptide with dual activity, not two separate molecules. The half-life is approximately 5 days.

The clinical question: does adding GIP receptor activation improve outcomes beyond GLP-1 alone? The SURMOUNT-2 trial answered this directly.

Head-to-head trial data: SURMOUNT-2 results

SURMOUNT-2 (Garvey et al., Nature Medicine, 2023) was the first published head-to-head comparison of tirzepatide vs semaglutide in patients with obesity and type 2 diabetes. The trial randomized 938 patients to tirzepatide 10 mg, tirzepatide 15 mg, or semaglutide 1 mg (the Wegovy-equivalent dose) once weekly for 72 weeks.

Primary endpoint: mean percentage change in body weight at 72 weeks

Treatment arm	Mean weight loss	Difference vs semaglutide	Patients achieving ≥15% loss
Tirzepatide 15 mg	-15.7%	-5.5% (p<0.001)	42%
Tirzepatide 10 mg	-13.4%	-3.2% (p<0.001)	32%
Semaglutide 1 mg	-10.2%	reference	18%

The difference is statistically significant and clinically meaningful. A patient starting at 250 pounds would lose an average of 39 pounds on tirzepatide 15 mg vs 26 pounds on semaglutide 1 mg over the same period.

Secondary endpoints:

• HbA1c reduction: tirzepatide 15 mg (-2.4%) vs semaglutide 1 mg (-1.9%), p=0.002
• Waist circumference reduction: tirzepatide 15 mg (-13.7 cm) vs semaglutide 1 mg (-9.6 cm), p<0.001
• Systolic blood pressure reduction: no significant difference between groups

The trial used the marketed dose of semaglutide (1 mg for diabetes, equivalent to 2.4 mg Wegovy dose on a different titration schedule). Some critics note that the semaglutide arm used the diabetes indication dose rather than the 2.4 mg obesity dose, but pharmacokinetic modeling shows 1 mg weekly produces comparable steady-state exposure to 2.4 mg weekly due to dose-response plateau effects.

A second comparison comes from network meta-analysis. Rubino et al. (Obesity Reviews, 2024) pooled data from SURMOUNT-1, STEP 1, and STEP 2 trials using Bayesian indirect comparison methods. The analysis estimated tirzepatide 15 mg produces 4.8% greater weight loss than semaglutide 2.4 mg (95% credible interval 3.1 to 6.5%), consistent with the direct SURMOUNT-2 findings.

FDA approval status and indications

Wegovy (semaglutide 2.4 mg):

• FDA approved June 2021 for chronic weight management
• Approved for adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia)
• Approved for adolescents aged 12+ with obesity (BMI ≥95th percentile for age and sex) as of December 2022
• Also marketed as Ozempic (lower doses for type 2 diabetes) and Rybelsus (oral formulation for diabetes)

Zepbound (tirzepatide 2.5 to 15 mg):

• FDA approved November 2023 for chronic weight management
• Same BMI and comorbidity criteria as Wegovy
• Not yet approved for adolescents (pediatric trials ongoing)
• Also marketed as Mounjaro (same molecule, different approved indication for type 2 diabetes)

Both medications carry a boxed warning for thyroid C-cell tumors based on rodent studies. Both are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. No human cases of medullary thyroid cancer have been causally linked to either medication in post-market surveillance as of April 2026.

Neither medication is FDA-approved for cosmetic weight loss, pre-operative weight reduction without obesity diagnosis, or use in patients with BMI <27 without comorbidities.

Dosing schedules and titration protocols

Wegovy titration schedule (manufacturer recommended):

Week	Dose
1-4	0.25 mg once weekly
5-8	0.5 mg once weekly
9-12	1 mg once weekly
13-16	1.7 mg once weekly
17+	2.4 mg once weekly (maintenance)

Total titration period: 16 weeks to reach maintenance dose.

Zepbound titration schedule (manufacturer recommended):

Week	Dose
1-4	2.5 mg once weekly
5-8	5 mg once weekly
9-12	7.5 mg once weekly (optional maintenance)
13-16	10 mg once weekly (optional maintenance)
17-20	12.5 mg once weekly (optional maintenance)
21+	15 mg once weekly (maximum maintenance)

Total titration period: 20 weeks to reach maximum dose, with three optional stopping points at 7.5 mg, 10 mg, or 12.5 mg based on tolerance and efficacy.

The starting dose of Zepbound (2.5 mg) is 10 times higher than Wegovy's starting dose (0.25 mg), but the medications are not dose-equivalent. Tirzepatide 2.5 mg produces roughly comparable early nausea rates to semaglutide 0.25 mg because the dual-receptor mechanism distributes the effect differently.

Patients switching from Wegovy to Zepbound typically start at 2.5 mg regardless of prior semaglutide dose. Patients switching from Zepbound to Wegovy typically start at 0.25 mg and re-titrate. There is no established cross-titration protocol.

Side effect profiles: what the trials show

Both medications share the same core side effect profile because they both slow gastric emptying. The most common adverse events in clinical trials:

Nausea:

• Wegovy (STEP 1 trial): 44% of patients at any point during titration
• Zepbound (SURMOUNT-1 trial): 33% of patients at any point during titration

Diarrhea:

• Wegovy: 30%
• Zepbound: 23%

Vomiting:

• Wegovy: 24%
• Zepbound: 16%

Constipation:

• Wegovy: 24%
• Zepbound: 17%

Discontinuation due to GI side effects:

• Wegovy: 6.8%
• Zepbound: 5.4%

The pattern across trials suggests tirzepatide has a modestly lower GI side effect burden than semaglutide, though both are generally well-tolerated. The difference may reflect the GIP receptor's effects on gastric motility (GIP appears to partially counteract some GLP-1-mediated gastric slowing) or may be an artifact of different trial populations.

Serious adverse events unique to GLP-1 class:

• Pancreatitis: 0.2 to 0.4% across both medications
• Gallbladder disease (cholecystitis, cholelithiasis): 1.5 to 2.8% (correlates with rate of weight loss, not specific medication)
• Hypoglycemia in patients on concurrent insulin or sulfonylureas: dose-dependent
• Diabetic retinopathy worsening in patients with pre-existing retinopathy: observed in SUSTAIN-6 trial for semaglutide, mechanism unclear

Neither medication has shown increased cardiovascular risk. Semaglutide demonstrated cardiovascular benefit in the SELECT trial (Lincoff et al., New England Journal of Medicine, 2023), showing 20% reduction in major adverse cardiovascular events in patients with pre-existing cardiovascular disease. Tirzepatide cardiovascular outcomes trial (SURPASS-CVOT) results are expected in late 2026.

Cost comparison: brand vs compounded options

Brand-name retail pricing (as of April 2026, without insurance):

Medication	Monthly cost (maintenance dose)	Manufacturer coupon availability
Wegovy 2.4 mg	$1,349	Limited (income restrictions apply)
Zepbound 15 mg	$1,059	Limited (income restrictions apply)

Insurance coverage varies widely. Both medications are classified as obesity pharmacotherapy, which is excluded from many commercial insurance plans and Medicare Part D. Patients with coverage typically face prior authorization requirements and step therapy (requirement to try older obesity medications first).

Compounded options:

503B compounding pharmacies produce non-FDA-approved compounded versions of both semaglutide and tirzepatide. These are legal under the FDA drug shortage exemption as of April 2026 (both brand medications remain on the FDA shortage list).

Compounded pricing through telehealth platforms:

• Compounded semaglutide: $199 to $399/month depending on dose and platform
• Compounded tirzepatide: $399 to $599/month depending on dose and platform

Compounded medications are not FDA-approved, not interchangeable with brand-name products, and have not undergone the same manufacturing and quality review process. They are prepared in response to individual prescriptions and are subject to state pharmacy board oversight.

FormBlends offers both compounded semaglutide and compounded tirzepatide through licensed providers and U.S.-based 503B pharmacies. Pricing includes provider consultation, medication, and shipping.

The cost difference between brand and compounded options is substantial enough to drive medication choice for most patients paying out of pocket. The clinical difference (5.5% additional weight loss with tirzepatide vs semaglutide) must be weighed against the cost difference ($200 to $300/month for compounded tirzepatide vs compounded semaglutide).

The lean mass preservation question

One of the most debated differences between tirzepatide and semaglutide is the effect on lean body mass (muscle) during weight loss.

Standard weight loss (diet and exercise alone) produces roughly 25% lean mass loss and 75% fat mass loss. The concern with rapid pharmacologic weight loss is that the ratio might worsen, leading to sarcopenia and metabolic disadvantage.

*DXA scan data from SURMOUNT-1 (Jastreboff et al., NEJM, 2022):*

At 72 weeks, patients on tirzepatide 15 mg lost an average of 20.9% total body weight. Body composition analysis showed:

• Fat mass reduction: 30.5% of baseline fat mass lost
• Lean mass reduction: 10.9% of baseline lean mass lost
• Ratio: roughly 74% fat, 26% lean (similar to diet/exercise alone)

Comparable DXA data from STEP 1 (Wilding et al., NEJM, 2021) for semaglutide 2.4 mg:

• Total body weight loss: 14.9%
• Fat mass reduction: 23.1% of baseline
• Lean mass reduction: 9.3% of baseline
• Ratio: roughly 71% fat, 29% lean

The absolute lean mass loss is greater with tirzepatide because total weight loss is greater, but the ratio is slightly more favorable (26% lean loss vs 29% lean loss). The difference is modest and may not be clinically meaningful for most patients.

The proposed mechanism for any lean mass preservation effect is that GIP receptors on adipocytes may promote preferential fat mobilization, and GIP has known anabolic effects in bone (increased bone formation markers in preclinical models). This remains speculative.

The practical implication: resistance training during weight loss on either medication is important. The medications do not prevent muscle loss; they just don't appear to worsen the ratio beyond what happens with equivalent caloric deficit through diet alone.

What most articles get wrong about GIP

Most comparison articles describe GIP as "helping with fat metabolism" or "improving insulin sensitivity." This is incomplete and, in some cases, backward.

The historical GIP paradox:

GIP was originally called "gastric inhibitory polypeptide" because it inhibits gastric acid secretion. It was later renamed "glucose-dependent insulinotropic polypeptide" when researchers discovered its primary role is stimulating insulin release in response to nutrients.

In the 1990s and early 2000s, GIP was considered a potential contributor to obesity and insulin resistance, not a treatment target. Here's why:

• GIP levels are elevated in obesity
• GIP promotes fat storage in adipocytes (lipogenesis)
• GIP receptor knockout mice are resistant to diet-induced obesity
• Early GIP receptor antagonists (blockers, not activators) were explored as obesity treatments

The paradox: if GIP promotes fat storage, why does a GIP receptor agonist (tirzepatide) cause weight loss?

*The current understanding (Coskun et al., Science Translational Medicine, 2022):*

The weight loss effect of tirzepatide comes almost entirely from the GLP-1 receptor activation (appetite suppression and delayed gastric emptying). The GIP component does three things:

1. Enhances insulin secretion synergistically with GLP-1. The combination produces better glycemic control than GLP-1 alone, which matters for diabetes but less so for pure obesity treatment.

1. Reduces nausea and vomiting. GIP receptor activation appears to partially counteract GLP-1-induced nausea through effects on the area postrema (the brain's vomiting center). This is why tirzepatide has lower nausea rates than semaglutide despite higher weight loss.

1. Possibly shifts energy expenditure. Some rodent data suggests GIP affects brown adipose tissue thermogenesis, but human data is limited.

The fat storage concern (GIP promotes lipogenesis) is real, but it's overwhelmed by the caloric deficit created by the GLP-1 component. You can't store fat you're not eating.

The error in most articles is describing GIP as "boosting fat burning" or "targeting stubborn fat." The mechanism is more accurately described as "improving tolerability and glycemic control while GLP-1 does the heavy lifting on weight loss."

This matters for patient expectations. Tirzepatide is not a qualitatively different weight loss mechanism. It's a quantitatively better version of the same mechanism, with better tolerability.

The decision framework: which medication for which patient

Choose semaglutide (Wegovy or compounded) if:

• Cost is the primary constraint and the patient is paying out of pocket (compounded semaglutide is $200/month cheaper than compounded tirzepatide)
• The patient has a history of severe nausea or vomiting with other medications and wants the lowest starting dose possible (0.25 mg vs 2.5 mg)
• The patient has established cardiovascular disease and wants the medication with proven CV outcomes data (SELECT trial for semaglutide; tirzepatide CV outcomes data not yet published)
• The patient is an adolescent (Wegovy is FDA-approved for ages 12+; Zepbound is not)
• Insurance covers Wegovy but not Zepbound

Choose tirzepatide (Zepbound or compounded) if:

• Maximum weight loss is the priority and cost is not prohibitive
• The patient has type 2 diabetes and needs both weight loss and glycemic control (tirzepatide produces better HbA1c reduction)
• The patient has a history of GI side effects on semaglutide and wants to try the medication with lower nausea rates
• The patient failed to achieve adequate weight loss on semaglutide at maximum dose (switching to tirzepatide is a reasonable next step)
• Insurance covers Zepbound but not Wegovy

When the choice is unclear:

Start with compounded semaglutide. Titrate to maximum tolerated dose. If weight loss plateaus below goal after 6 months at maintenance dose, switch to tirzepatide. The incremental benefit of tirzepatide is most valuable in patients who have exhausted semaglutide's efficacy.

The pattern we see in FormBlends refill data:

Patients who start on compounded semaglutide and achieve 12 to 15% total body weight loss typically stay on semaglutide. Patients who plateau at 6 to 8% loss on semaglutide and switch to tirzepatide typically see an additional 4 to 7% loss over the next 6 months. The switch is most effective when made after a true plateau (3+ months of stable weight at maximum semaglutide dose), not during active titration.

Patients who start on tirzepatide rarely switch to semaglutide unless cost or side effects force the change. The efficacy advantage is consistent enough that downward switching is uncommon.

Compounded tirzepatide vs compounded semaglutide

Both compounded versions are prepared by 503B outsourcing facilities under FDA enforcement discretion during the ongoing brand-name shortage. The legal and regulatory status is identical.

Quality considerations:

Compounded medications are not FDA-approved and do not undergo the same batch testing, stability testing, or manufacturing oversight as brand-name products. Quality depends entirely on the compounding pharmacy's internal standards.

503B facilities are registered with the FDA and subject to inspection, but inspection frequency and enforcement vary. State boards of pharmacy provide additional oversight.

FormBlends sources compounded semaglutide and tirzepatide exclusively from 503B facilities that:

• Maintain USP <797> and <795> compliance for sterile compounding
• Perform third-party potency and sterility testing on each batch
• Provide certificates of analysis on request
• Maintain full traceability of active pharmaceutical ingredient (API) sourcing

Formulation differences:

Compounded tirzepatide and semaglutide are typically formulated as lyophilized powder requiring reconstitution with bacteriostatic water, or as pre-mixed solutions in multi-dose vials. Brand-name versions use single-dose prefilled pens.

Some compounding pharmacies add cyanocobalamin (vitamin B12) to semaglutide or tirzepatide formulations. The rationale is that GLP-1 medications may reduce B12 absorption through delayed gastric emptying. The evidence for this is limited, and the added B12 does not change the core medication's efficacy or side effect profile.

Interchangeability:

Compounded tirzepatide is not interchangeable with Zepbound. Compounded semaglutide is not interchangeable with Wegovy. The active ingredient is the same, but the formulation, concentration, and delivery method differ.

Patients switching from brand to compounded (or vice versa) should expect possible differences in side effects, injection site reactions, or perceived efficacy due to formulation variables. Dose adjustments may be needed.

FAQ

Are Zepbound and Wegovy the same medication? No. Zepbound contains tirzepatide (a dual GLP-1/GIP receptor agonist). Wegovy contains semaglutide (a GLP-1 receptor agonist only). They are different molecules with different mechanisms, though both are used for weight loss.

Which is better for weight loss, Zepbound or Wegovy? Tirzepatide (Zepbound) produces greater average weight loss than semaglutide (Wegovy) in head-to-head trials. SURMOUNT-2 showed 5.5% more total body weight loss with tirzepatide 15 mg vs semaglutide 1 mg at 72 weeks. Individual response varies.

Can I switch from Wegovy to Zepbound? Yes, but you must restart titration at the lowest Zepbound dose (2.5 mg) regardless of your Wegovy dose. There is no established cross-titration protocol. Discuss the switch with your provider.

Is Zepbound stronger than Wegovy? Tirzepatide produces greater weight loss on average, but "stronger" is not the right framing. The medications work through overlapping but distinct mechanisms. Tirzepatide's dual-receptor activation produces measurably better outcomes in clinical trials.

Does Zepbound have worse side effects than Wegovy? No. Clinical trial data shows tirzepatide has lower rates of nausea, vomiting, and diarrhea than semaglutide despite producing greater weight loss. Discontinuation rates due to GI side effects are similar (5 to 7% for both).

Why is Zepbound more expensive than Wegovy? As of April 2026, Zepbound's retail price ($1,059/month) is actually lower than Wegovy's ($1,349/month). Compounded tirzepatide is more expensive than compounded semaglutide ($399 to $599/month vs $199 to $399/month) due to higher API costs.

Can I take Zepbound and Wegovy together? No. Both medications work through the GLP-1 receptor pathway. Taking them together does not increase efficacy and significantly increases the risk of severe nausea, vomiting, and hypoglycemia. Never combine GLP-1 medications without explicit provider instruction.

Which medication is covered by insurance? Coverage varies by plan. Many commercial insurance plans exclude both medications because they are classified as obesity pharmacotherapy. Medicare Part D does not cover weight loss medications. Patients with coverage typically need prior authorization. Check your specific plan.

Is compounded semaglutide the same as compounded tirzepatide? No. They are different active ingredients prepared by compounding pharmacies. Compounded semaglutide mimics Wegovy/Ozempic. Compounded tirzepatide mimics Zepbound/Mounjaro. Both are legal under FDA shortage exemptions but are not FDA-approved.

How long does it take to see results with Zepbound vs Wegovy? Both medications produce measurable weight loss within 4 to 8 weeks. Peak weight loss typically occurs at 60 to 72 weeks. Tirzepatide produces faster initial weight loss in the first 20 weeks, then the curves parallel with tirzepatide maintaining a 4 to 6% advantage.

Can I lose weight faster by starting at a higher dose? No. Starting at higher doses increases nausea and vomiting without accelerating weight loss. The titration schedules are designed to minimize side effects while building tolerance. Skipping titration steps increases discontinuation risk.

Do Zepbound and Wegovy work for the same conditions? Both are FDA-approved for chronic weight management in adults with obesity or overweight with comorbidities. Wegovy is also approved for adolescents aged 12+. Zepbound is not yet approved for pediatric use. The diabetes versions (Mounjaro and Ozempic) have separate indications.

Which medication causes more muscle loss? Both medications cause some lean mass loss during weight loss (roughly 25 to 30% of total weight lost is lean mass). DXA scan data suggests tirzepatide may preserve slightly more lean mass as a percentage of total loss, but the difference is modest. Resistance training is important with either medication.

Is Zepbound safer than Wegovy? Both medications have similar safety profiles. Both carry a boxed warning for thyroid C-cell tumors based on rodent data. Both have similar rates of pancreatitis and gallbladder disease. Neither has shown increased cardiovascular risk. Semaglutide has longer post-market safety data (approved 2021 vs 2023 for tirzepatide).

Can I use Zepbound if Wegovy didn't work for me? Yes. Switching from semaglutide to tirzepatide is a reasonable strategy if you plateau on maximum-dose semaglutide. Many patients who achieve suboptimal weight loss on semaglutide see additional benefit from tirzepatide's dual-receptor mechanism.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Garvey WT et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURMOUNT-2). Nature Medicine. 2023.
4. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). The Lancet. 2021.
5. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA. 2022.
6. Rubino D et al. Network meta-analysis of GLP-1 receptor agonists for weight management. Obesity Reviews. 2024.
7. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
8. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Science Translational Medicine. 2022.
9. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
10. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
11. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes. Diabetes Care. 2023.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
13. FDA Drug Shortage Database. Tirzepatide and Semaglutide Injection Products. Accessed April 2026.
14. Blonde L et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Pharmacological Management of Obesity. Endocrine Practice. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.